Takeda Closes Global Oncology Partnership with Innovent Biologics

Takeda has closed its previously announced license and collaboration agreement with Innovent Biologics, securing rights outside Greater China to two late-stage investigational oncology medicines, IBI363 and IBI343. The deal positions Takeda to advance global development and commercialization of these candidates, which target multiple solid tumor types with significant unmet medical needs.

Expanded Rights Strengthen Takeda’s Oncology Pipeline

Under the agreement, Takeda will lead global co-development and U.S. co-commercialisation of IBI363, with exclusive commercialisation rights in all other territories outside Greater China, as well as shared manufacturing rights for the U.S. market. For IBI343, Takeda holds exclusive global development, manufacturing, and commercialization rights outside Greater China and plans to build U.S.-based manufacturing capabilities for both programs.

Large Upfront Investment Signals Long-Term Strategic Commitment

Takeda has closed its previously announced license and collaboration agreement with Innovent Biologics, securing rights outside Greater China to two late-stage investigational oncology medicines, IBI363 and IBI343. The deal positions Takeda to advance global development and commercialization of these candidates, which target multiple solid tumor types with significant unmet medical needs.